TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2174277

Group type: EXPERIMENTAL
Intervention: Cis-platin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carboplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regimens including radiotherapy after chemotherapy
Number of subjects: 0
Study: 30896987

Group type: EXPERIMENTAL
Intervention: DBN+SS laws
Number of subjects: 1441544

Group type: COMPARATOR
Intervention: No DBN law
Number of subjects: 1441544

Group type: COMPARATOR
Intervention: Generic DBN laws
Number of subjects: 1441544
Study: 30056127

Group type: EXPERIMENTAL
Intervention: Single-dose 0.5% ropivacaine paravertebral block (PVB) with patient-controlled intravenous analgesia (PCIA)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Single-dose 0.5% ropivacaine and dexmedetomidine (1 μg/kg) PVB with PCIA
Number of subjects: 114

Group type: COMPARATOR
Intervention: Intraoperative thoracic epidural anesthesia with 0.5% ropivacaine and single dose of epidural morphine (0.03 mg/kg) with PCIA
Number of subjects: 114
Study: 27475714

Group type: EXPERIMENTAL
Intervention: Closed‐chain and open‐chain exercises focusing on rotator cuff and scapulothoracic muscles for four weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study: 25250722

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous immunoglobulins (IVIG) treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control IgG from healthy and diseased controls
Number of subjects: 18
Study: 22708798

Group type: EXPERIMENTAL
Intervention: Aminolaevulinate photodynamic therapy (PDT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CO(2) laser ablation (LA)
Number of subjects: 20
Study: 21698545

Group type: EXPERIMENTAL
Intervention: NY‐ESO‐1 protein with ISCOMATRIX™ adjuvant (10 μg, 30 μg, or 100 μg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 100 μg un‐adjuvanted NY‐ESO‐1 protein
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 2 μg DTH protein
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: DTH skin testing with NY‐ESO‐1 protein (1 μg) or peptides (10 μg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Relapse-free survival
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Tumour NY‐ESO‐1 or HLA class I
Number of subjects: 28
Study: 17415632

Group type: EXPERIMENTAL
Intervention: Antibiotics as adjunct therapy to conventional treatment (corticosteroids and 5-aminosalycilic acid)
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Antibiotics (short-term trials of 5-14 days)
Number of subjects: 530
Study: 15667818

Group type: EXPERIMENTAL
Intervention: Hands-free phone tasks (artificial math operations)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hands-free phone tasks (emotionally involving conversation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Driving tasks with greater demands
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older drivers
Number of subjects: 0
Study: 11898014

Group type: EXPERIMENTAL
Intervention: Chiropractic care with physical modalities
Number of subjects: 341

Group type: COMPARATOR
Intervention: Chiropractic care without physical modalities
Number of subjects: 341
Study: 10216089

Group type: EXPERIMENTAL
Intervention: Standard therapy plus 300 mg vitamin E twice daily (n = 9)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: In vitro vitamin E (50 micromol/L)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard therapy (n = 5)
Number of subjects: 30
Study: 8848526

Group type: EXPERIMENTAL
Intervention: Bretazenil (1 mg)
Number of subjects: 10
Study: 2191890

Group type: EXPERIMENTAL
Intervention: Prophylactic vitamin E supplementation
Number of subjects: 0
Study: 155707

Group type: EXPERIMENTAL
Intervention: Self-instruction, self-evaluation
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Self-instruction, teacher-evaluation
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Teacher-aided instruction, self-evaluation
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Teacher-aided instruction, teacher-evaluation
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Supplemental lecture (given to half of each group)
Number of subjects: 27
Study: 31090749

Group type: EXPERIMENTAL
Intervention: Natural position (central group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Palatal position (palatal group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 20
Study: 28457318

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (4.4 g daily providing 2.6 g eicosapentaenoic acid and 1.8 g docosahexaenoic acid)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 80
Study: 26438703

Group type: EXPERIMENTAL
Intervention: Bidirectional short messaging service (up to 3 personalized messages)
Number of subjects: 4587

Group type: COMPARATOR
Intervention: Control group (no messaging service)
Number of subjects: 4587

Group type: EXPERIMENTAL
Intervention: Response option '1' (clinic will call to schedule)
Number of subjects: 4587
Study: 23934907

Group type: COMPARATOR
Intervention: Well-functioning implants
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sub-optimal functioning implants
Number of subjects: 48
Study: 20647959

Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) users with CRP levels of 3 mg/L or higher
Number of subjects: 25991

Group type: COMPARATOR
Intervention: Nonusers with CRP levels of 3 mg/L or higher
Number of subjects: 25991

Group type: EXPERIMENTAL
Intervention: Logarithm CRP levels for HT users
Number of subjects: 25991

Group type: COMPARATOR
Intervention: Logarithm CRP levels for HT nonusers
Number of subjects: 25991
Study: 19662783

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (640 mcg of budesonide and 18 mcg of formoterol daily)
Number of subjects: 268
Study: 16435613

Group type: EXPERIMENTAL
Intervention: Spinal morphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 60
Study: 12938571

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 0
Study: 10588996

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 23

Group type: COMPARATOR
Intervention: Cromolyn
Number of subjects: 23

Group type: COMPARATOR
Intervention: Beclomethasone
Number of subjects: 23
Study: 8948369

Group type: COMPARATOR
Intervention: Nucleoside or non-nucleoside analog reverse transcriptase inhibitors
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Combination nucleoside analog therapy
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ritonavir (HIV protease inhibitor) monotherapy
Number of subjects: 7
Study: 1755436

Group type: EXPERIMENTAL
Intervention: Concentration problems
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Poor achievement
Number of subjects: 2400
Study: 6185222

Group type: EXPERIMENTAL
Intervention: Tiapamil (0.3-1.5 mg/kg bolus doses)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Tiapamil (12-25 mg/h continuous infusion)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Tiapamil (1 mg/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Verapamil (0.13 mg/kg)
Number of subjects: 32
Study: 29848343

Group type: EXPERIMENTAL
Intervention: Music therapy (Trauma‐focused Music and Imagery, TMI)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Verbal psychotherapy (standard treatment)
Number of subjects: 70
Study: 28008004

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive-behavioral pain intervention with goal agreement
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive-behavioral pain intervention with physically active goal agreement
Number of subjects: 122

Group type: COMPARATOR
Intervention: Internet-delivered cognitive-behavioral pain intervention with no goal agreement
Number of subjects: 122
Study: 25483830

Group type: EXPERIMENTAL
Intervention: 15-month PA and F&V intervention
Number of subjects: 582
Study: 23252601

Group type: EXPERIMENTAL
Intervention: Chemoprevention intervention
Number of subjects: 471
Study: 22027731

Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon (DEB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular balloon
Number of subjects: 0
Study: 18315426

Group type: EXPERIMENTAL
Intervention: SDD-40 (40 mg doxycycline, once daily)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study: 17060062

Group type: EXPERIMENTAL
Intervention: olmesartan 20 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: olmesartan 20 mg plus glibenclamide 3.5 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: glibenclamide 3.5 mg
Number of subjects: 18
Study: 15228823

Group type: EXPERIMENTAL
Intervention: Prophylaxis for VTE (group-A)
Number of subjects: 249

Group type: COMPARATOR
Intervention: No prophylaxis for VTE (group-B)
Number of subjects: 249
Study: 11426360

Group type: EXPERIMENTAL
Intervention: Intravenous milrinone (50 microg/kg during 10 minutes followed by 0.5 microg/kg/min)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intravenous dobutamine (10 to 20 microg/kg/min)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intravenous milrinone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intravenous dobutamine
Number of subjects: 120
Study: 9402176

Group type: EXPERIMENTAL
Intervention: VEGF concentration in aqueous fluid of the anterior chamber of the eye
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: VEGF concentration in serum
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: VEGF concentration in urine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: VEGF concentration in fluid from renal cysts
Number of subjects: 15

Group type: COMPARATOR
Intervention: Concentrations of bFGF, IL-8, and ET-1 in serum and urine
Number of subjects: 15
Study: 8435895

Group type: EXPERIMENTAL
Intervention: Continuous 24-hour infusion of 2 IU GH
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Two intravenous boluses of 2 IU GH
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Eight intravenous boluses of 2 IU GH every 3 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single subcutaneous injection of 0.2 U/kg GH
Number of subjects: 12

Group type: COMPARATOR
Intervention: Untreated normal controls
Number of subjects: 12
Study: 2441642

Group type: EXPERIMENTAL
Intervention: nicergoline
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 31917129

Group type: EXPERIMENTAL
Intervention: Multicomponent family-based prevention program
Number of subjects: 255

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 255
Study: 28864265

Group type: EXPERIMENTAL
Intervention: Hybrid group (continuous motion parameter feedback)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Regular box group (no motion parameter feedback)
Number of subjects: 36
Study: 27146827

Group type: EXPERIMENTAL
Intervention: Vaginal gel
Number of subjects: 2750

Group type: EXPERIMENTAL
Intervention: Oral tablet
Number of subjects: 2750
Study: 24996416

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Better health state
Number of subjects: 0
Study: 23252208

Group type: EXPERIMENTAL
Intervention: 0.2% bupivacaine with adrenaline
Number of subjects: 47

Group type: COMPARATOR
Intervention: 0.9% NSS
Number of subjects: 47
Study: 19651405

Group type: EXPERIMENTAL
Intervention: Disease management programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 18450928

Group type: EXPERIMENTAL
Intervention: Neurocognition and symptoms
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: Positive syndrome scale of PANSS
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: Neurocognition and symptom measures during treatment
Number of subjects: 1386
Study: 16184439

Group type: EXPERIMENTAL
Intervention: Prophylactic carotid endarterectomy (CEA) within 1 week before major surgery
Number of subjects: 79

Group type: COMPARATOR
Intervention: Deferred carotid endarterectomy (CEA) between 30 days and 6 months after major surgery
Number of subjects: 79
Study: 12637464

Group type: EXPERIMENTAL
Intervention: Arzoxifene 20 mg
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Arzoxifene 50 mg
Number of subjects: 112
Study: 11131781

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (400 microg)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 microg)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Second dose of oral misoprostol (400 microg)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Both routes of administration
Number of subjects: 237
Study: 8931083

Group type: EXPERIMENTAL
Intervention: Synchronized intermittent mandatory ventilation (SIMV)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Assist/control (A/C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional intermittent mandatory ventilation (IMV)
Number of subjects: 12
Study: 1306633

Group type: EXPERIMENTAL
Intervention: 24-hour nicotine delivery
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Nicotine delivery during wakeful hours only
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches
Number of subjects: 158
Study: 3511821

Group type: EXPERIMENTAL
Intervention: ProMACE‐CytaBOM
Number of subjects: 69

Group type: COMPARATOR
Intervention: ProMACE‐MOPP
Number of subjects: 69
Study: 31713442

Group type: EXPERIMENTAL
Intervention: Physical activity intervention over 6 months
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Sleep quality
Number of subjects: 247
Study: 30513970

Group type: EXPERIMENTAL
Intervention: Ketogenic drink (KD 4:1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketogenic drink (KD 1.7:1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Balanced nutrition drink (BD)
Number of subjects: 0
Study: 27756567

Group type: EXPERIMENTAL
Intervention: Active tDCS (2.5mA, 20 sessions of 30min duration over 4 weeks)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham tDCS (2.5mA, 20 sessions of 30min duration over 4 weeks)
Number of subjects: 120
Study: 23635729

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (no levonorgestrel-releasing intrauterine system)
Number of subjects: 129
Study: 21364487

Group type: EXPERIMENTAL
Intervention: Passive Heating (PaH)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Exercise-Induced Hyperthermia (ExH)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study: 19843783

Group type: COMPARATOR
Intervention: Intrathecal 10 mg lidocaine 2% plus 10 microg fentanyl (Group I)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Intrathecal 3 mg levobupivacaine 0.5% plus 10 microg fentanyl (Group II)
Number of subjects: 52
Study: 17199533

Group type: EXPERIMENTAL
Intervention: Autologous fibroblast injections
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 20
Study: 15262418

Group type: EXPERIMENTAL
Intervention: Nystatin incorporated into gel and suspension formulations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chitosan gel alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nystatin suspension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nystatin formulations
Number of subjects: 0
Study: 11816552

Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Racemate omeprazole
Number of subjects: 0
Study: 9609412

Group type: EXPERIMENTAL
Intervention: Enteral ciprofloxacin 750 mg b.i.d.
Number of subjects: 5

Group type: COMPARATOR
Intervention: Intravenous ciprofloxacin 400 mg b.i.d.
Number of subjects: 5
Study: 7810782

Group type: EXPERIMENTAL
Intervention: Semi-rigid ankle orthosis (Sport-Stirrup)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Control group (non-braced) with previous sprains
Number of subjects: 504

Group type: COMPARATOR
Intervention: Control group (non-braced) without previous sprains
Number of subjects: 504
Study: 3185292

Group type: EXPERIMENTAL
Intervention: TTS‐oestradiol 50 micrograms
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conjugated oestrogens 1.25 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Oestradiol valerate 2 mg
Number of subjects: 13
Study: 31230222

Group type: EXPERIMENTAL
Intervention: Combined treatment of donepezil hydrochloride and choline supplement
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28351897

Group type: EXPERIMENTAL
Intervention: Predictive low glucose management (PLGM ON)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sensor-augmented insulin pump with PLGM OFF
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PLGM ON
Number of subjects: 100
Study: 24802530

Group type: EXPERIMENTAL
Intervention: Combination treatment with adapalene 0.1% gel and ketoconazole 2% cream once daily for 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ketoconazole 2% cream twice daily for 2 weeks (monotherapy group)
Number of subjects: 0
Study: 23331844

Group type: EXPERIMENTAL
Intervention: 1000 mg testosterone undecanoate (n = 10)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 21
Study: 21463970

Group type: EXPERIMENTAL
Intervention: Spinal Manipulative Techniques (SMT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 90

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 90
Study: 18398586

Group type: EXPERIMENTAL
Intervention: Irradiation for prophylaxis of heterotopic ossification (HO)
Number of subjects: 0
Study: 21241828

Group type: EXPERIMENTAL
Intervention: Comprehensive intensive management of CVD risk factors for one year by a nurse practitioner/community health worker (NP/CHW) team
Number of subjects: 525

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 525
Study: 16042028

Group type: EXPERIMENTAL
Intervention: Referential communication task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cookie Theft Picture Description test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CADL test
Number of subjects: 0
Study: 12477584

Group type: EXPERIMENTAL
Intervention: rapacuronium 0.25 mg x kg(‐1) i.v. (Group 1)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: rapacuronium 0.5 mg x kg(‐1) i.v. (Group 2)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: rapacuronium 0.75 mg x kg(‐1) i.v. (Group 3)
Number of subjects: 69
Study: 9804031

Group type: EXPERIMENTAL
Intervention: Theory of mind tasks (including an emotion prediction task involving either a nice or a nasty surprise)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Emotion understanding stories (requiring affective perspective-taking skills and situational understanding)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Simple executive function tasks (adapted for preschoolers, tapping inhibitory control, attentional set-shifting, and working memory)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Executive function performance
Number of subjects: 40
Study: 7637161

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.2 mg‐1.0 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Midazolam 5 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 31
Study: 2693557

Group type: EXPERIMENTAL
Intervention: Human amniotic fluid (HAF) as a complete medium
Number of subjects: 0

Group type: COMPARATOR
Intervention: T6 + 10% HS medium
Number of subjects: 0
Study: 657108

Group type: EXPERIMENTAL
Intervention: Intralesional Bacillus Calmette-Guerin (BCG)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intralesional dinitrochlorobenzene (DNCB)
Number of subjects: 18
Study: 29507124

Group type: EXPERIMENTAL
Intervention: Intensive audit and feedback with daily-updated team-based data dashboard and weekly in-person review of performance data ('STAT rounds')
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual audit and feedback with ongoing twice-monthly emails with graphical depictions of team performance
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Washout period after cessation of STAT rounds
Number of subjects: 40
Study: 27449404

Group type: EXPERIMENTAL
Intervention: Ramosetron (0.3 mg)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Ondansetron (4 mg)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo (2 ml)
Number of subjects: 105
Study: 25337035

Group type: EXPERIMENTAL
Intervention: RBC transfusion at a Hb threshold of 8.9 g/dL (liberal group)
Number of subjects: 66

Group type: COMPARATOR
Intervention: RBC transfusion at a Hb threshold of 7.3 g/dL (restrictive group)
Number of subjects: 66
Study: 23507372

Group type: EXPERIMENTAL
Intervention: Maternal HIV infection
Number of subjects: 1502

Group type: EXPERIMENTAL
Intervention: Young maternal age, low maternal education, low birth weight, early weaning, higher number of episodes of malaria during infancy
Number of subjects: 1502

Group type: EXPERIMENTAL
Intervention: Higher number of living children in the family
Number of subjects: 1502

Group type: COMPARATOR
Intervention: Stunting
Number of subjects: 1502

Group type: COMPARATOR
Intervention: Underweight
Number of subjects: 1502

Group type: COMPARATOR
Intervention: Wasting
Number of subjects: 1502
Study: 20018364

Group type: EXPERIMENTAL
Intervention: 7.5 microg non-adjuvant split-virion vaccine
Number of subjects: 12691

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12691
Study: 18278987

Group type: EXPERIMENTAL
Intervention: Risperidone augmentation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 16025970

Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex) combined with Ginsenosides (GS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dexamethasone (Dex)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ginsenosides (GS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 12946740

Group type: EXPERIMENTAL
Intervention: Alfuzosin 5 mg twice daily
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control/Standard therapy
Number of subjects: 66
Study: 11062287

Group type: EXPERIMENTAL
Intervention: Contralateral severe ICA stenosis (70% to 99%)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Lesser degrees of contralateral ICA stenosis (less than 70%)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Lesser degrees of contralateral ICA stenosis (11 to 21 cm/s)
Number of subjects: 386